Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

December 30, 2021

Primary Completion Date

July 3, 2024

Study Completion Date

August 29, 2024

Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG

RMC-4630

RMC-4630 administered orally as a capsule

DRUG

Sotorasib

Sotorasib administered orally as a tablet

Trial Locations (60)

704

National Cheng Kung University Hospital, Tainan City

807

Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung City

824

E-DA Hospital, Kaohsiung City

2148

Blacktown Hospital, Blacktown

3280

South West Oncology, Warrnambool

3630

Goulburn Valley Health, Shepparton

10002

National Taiwan University Hospital, Taipei

10021

Clinical Research Alliance, Inc., New York

10043

Azienda Sanitaria Ospedaliera S Luigi Gonzaga, Orbassano

12200

Charite Benjamin Franklin Comprehensive Cancer center, Berlin

13015

APHM Hopital Nord, Service d'Oncologie Multidisciplinaire et innovations therapeutics, Marseille

13125

Evangelische Lung Clinic, Berlin

14263

Roswell Park cancer Institute, Buffalo

15006

Complejo Hospitalario Universitario A Coruña, A Coruña

20141

Istituto Europeo Di Oncologia, Milan

20251

Hamato-Onkologie Hamburg, Hamburg

20817

American Oncology Partners of Maryland, PA, Bethesda

21044

Maryland Oncology Hematology, P.A., Columbia

22031

Virginia Cancer Specialists, Fairfax

23502

Virginia Oncology Associates, Norfolk

28027

Clinica Universidad de Navarra, Madrid

28644

Chungbuk National University Hospital, Cheongju-si

29414

Charleston Oncology, Charleston

31008

Clinica Universidad de Navarra, Pamplona

31059

Hospital Larrey Universite Paul Sabatier, Toulouse

32086

Cancer Specialists of North Florida, Saint Augustine

33322

BRCR Medical Center Inc., Plantation

33901

Florida Cancer Specialists, Fort Myers

37203

Sarah Cannon Research Institute, Nashville

37404

Tennessee Oncology, Chattanooga

40705

Taichung Veterans General Hospital, Taichung

41009

Hospital Universitario Virgen Macarena, Seville

43219

Zangmeister Cancer Center, Columbus

46026

Hospital Universitario y Politecnico La Fe, Valencia

47441

Bethanien Hospital Moers, Moers

55404

Minnesota Oncology Hematology, P.A., Minneapolis

58675

Lungenklinik Hemer, Hemer

60805

GenHarp Clinical Solutions, Evergreen Park

66421

Comprehensive Cancer Center Mainfranken, University Wuerzburg, Homburg

Lung Cancer Center, University of Saarland, Homburg

68130

Nebraska Cancer Specialists, Omaha

70809

Hematology Oncology Clinic, Baton Rouge

73730

Klinikum Esslingen GmbH, Esslingen am Neckar

75503

CHRISTUS St. Michael-Colom and Carney Clinic P.A, Texarkana

80131

Azienda Ospedaliera dei Colli, Napoli

82131

Asklepios Fachkliniken Munchen, Gauting

87131

University of New Mexico Comprehensive Cancer Center, Albuquerque

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

98684

Northwest Cancer specialists, P.C., Vancouver

04074

New England Cancer Specialists, Scarborough

08724

New Jersey Center for Cancer Research, Brick

T6G 1Z2

Cross Cancer Institute, Edmonton

L5N 5M8

William Osler Health System, Mississauga

04347

POIS Sachsen GmbH, Leipzig

03080

Seoul National University Hospital, Seoul

05505

Asan Medical Center, Seoul

06351

Samsung Medical Center, Seoul

08036

Hospital Clinic de Barcelona, Barcelona

M20 4BX

The Christie NHS Foundation Trust, Manchester

SM2 5PT

The Royal Marsden NHS Foundation Trust, Sutton

Sponsors

Collaborators (2)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

collaborator

Amgen

INDUSTRY

lead

Revolution Medicines, Inc.

INDUSTRY